The complement system is recognised as a protector against blood-borne pathogens and a
controller of immune system and tissue homoeostasis. However, dysregulated complement …

Thrombotic microangiopathy (TMA) is characterized by thrombocytopenia, microangiopathic
haemolytic anaemia and end organ damage. TMAs have varying underlying …

In the last decade, a deeper understanding of the pathogenesis of complement mediated
hemolytic disorders, such as paroxysmal nocturnal hemoglobinuria (PNH), cold agglutinin …

The syndrome of thrombotic microangiopathy (TMA) is a clinical-pathological entity
characterized by microangiopathic hemolytic anemia, thrombocytopenia, and end organ …

ABSTRACT A refined understanding of the role of complement in the pathogenesis of
glomerular and other kidney diseases has, over the past two decades, been matched by the …

Atypical hemolytic uremic syndrome (aHUS) is a rare disorder characterized by
dysregulation of the alternate pathway. The diagnosis of aHUS is one of exclusion, which …

Ravulizumab (Ultomiris®), a humanized monoclonal antibody that inhibits complement
protein C5, is indicated for the treatment of atypical haemolytic uraemic syndrome (aHUS) in …

The complement pathway is an essential mechanism in innate immunity, but it is also
involved in multiple pathologies. For kidney diseases, strong evidence of a dysregulation in …

Ravulizumab and eculizumab are approved terminal complement inhibitor treatments for
atypical hemolytic uremic syndrome (aHUS). Ravulizumab was engineered from eculizumab …

The complement system is part of the innate immune system. The crucial step in activating
the complement system is the generation and regulation of C3 convertase complexes, which …